1. A TRPC3/6 Channel Inhibitor Promotes Arteriogenesis after Hind-Limb Ischemia.
- Author
-
Shimauchi, Tsukasa, Numaga-Tomita, Takuro, Kato, Yuri, Morimoto, Hiroyuki, Sakata, Kosuke, Matsukane, Ryosuke, Nishimura, Akiyuki, Nishiyama, Kazuhiro, Shibuta, Atsushi, Horiuchi, Yutoku, Kurose, Hitoshi, Kim, Sang Geon, Urano, Yasuteru, Ohshima, Takashi, and Nishida, Motohiro
- Subjects
- *
MUSCLE mass , *VASCULAR smooth muscle , *PERIPHERAL circulation , *PERIPHERAL vascular diseases , *BLOOD flow , *ENDOTHELIUM , *ENDOTHELIUM diseases - Abstract
Retarded revascularization after progressive occlusion of large conductance arteries is a major cause of bad prognosis for peripheral artery disease (PAD). However, pharmacological treatment for PAD is still limited. We previously reported that suppression of transient receptor potential canonical (TRPC) 6 channel activity in vascular smooth muscle cells (VSMCs) facilitates VSMC differentiation without affecting proliferation and migration. In this study, we found that 1-benzilpiperadine derivative (1-BP), a selective inhibitor for TRPC3 and TRPC6 channel activities, induced VSMC differentiation. 1-BP-treated mice showed increased capillary arterialization and improvement of peripheral circulation and skeletal muscle mass after hind-limb ischemia (HLI) in mice. 1-BP had no additive effect on the facilitation of blood flow recovery after HLI in TRPC6-deficient mice, suggesting that suppression of TRPC6 underlies facilitation of the blood flow recovery by 1-BP. 1-BP also improved vascular nitric oxide bioavailability and blood flow recovery after HLI in hypercholesterolemic mice with endothelial dysfunction, suggesting the retrograde interaction from VSMCs to endothelium. These results suggest that 1-BP becomes a potential seed for PAD treatments that target vascular TRPC6 channels. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF